Notifications
Back

Scientific Research

At OSR Holdings, we are committed to advancing transformative therapies grounded in rigorous scientific research. Below are selected publications and conference abstracts that provide scientific context for our programs and the underlying biology of our pipeline candidates.

Scientific Research

At OSR Holdings, we are committed to advancing impactful therapies grounded in rigorous scientific research. Below are selected publications and conference abstracts that provide scientific context for our programs and the underlying biology of our pipeline candidates.

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

Events & Presentation copy
4 Sep 2025

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

Cancer Vaccines as Enablers of Immunotherapy A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma
List New post

OSR Holdings　　Reg No. 589-86-01485

Email. group@osr-holdings.com


US: 10900 NE 4th Street, 2300 Bellevue, WA 98004
KR: B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
CH: Technologiepark Basel, Hochbergerstrasse 60c

Copyright © OSR Holdings, Inc. All Rights Reserved.



              

OSR Holdings, Inc.　　Reg No. 589-86-01485　　Email. group@osr-holdings.com

U.S  10900 NE 4th Street, 2300 Bellevue, WA 98004

Korea, Republic of  B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do 
Switzerland  Technologiepark Basel, Hochbergerstrasse 60c, CH-4057


Copyright © OSR Holdings, Inc. All Rights Reserved.